As personalized medicine and the discovery of de novo variants that cause disease continue to grow, researchers are increasingly in need of alternative models
Inflammation in your intestine is detrimental to overall health, and can create many complications. So how is this phenomenon researched?
Traditional modeling of patient variants in vivo has two limitations which can be overcome utilizing InVivo Biosystems’ patented WHAM-method.
Current in vivo platforms are limited in their ability to identify drug candidates – Whole-gene Humanized Animal Models can help.
Summary Rare diseases are just that: rare. However, when combined rare diseases affect 3.5% – 5.9% of the worldwide population, and present a growing healthcare
In this article, we will discuss the commonly used model organisms for microbiome research, and what insights they can provide.
What is the microbiome? How does it help or hinder health? And, what does recent research indicate? We’ve all had that regret: “oh, I should
Using Humanization we can take advantage of the ancient biology between humans and other organisms to create stand-ins – patient avatars – for drug screening studies. In this blog, we will focus on models of inborn errors of metabolism (IEM), as these genetic conditions can lead to hypersensitivity to the metabolite. Since stressor condition hypersensitivity can be used to detect favorable drug effects, IEM model systems are ideal tools for phenotypic screens to find molecules that alleviate the metabolic stress occurring from the deficiency. We discuss the model organisms used in hypersensitivity screens, and why they are advantageous to drug discovery. Ultimately, showcasing this approach’s potential to be widely generalized to many genetic disorders.
Reactive oxygen species (ROS) are free radicals that have been found to extend lifespan at low levels, however, they are lethal at higher doses. So is the saying ‘what doesn’t kill you make you stronger’ true? Or should free radicals be avoided as much as possible? In this article we discuss the current paradoxical findings, and focus on genetic disorders such as Progeria which is characterized by rapid aging and elevated ROS levels.
Bottom line: Getting some SSSH! time with this split-hygR technique can calm the frustration of the aggravated C. elegans researcher.
We have found whole gene humanization can create a platform for highly translatable results in a model organism. Currently there is a big need for functional studies of Variants of Uncertain Significance (VUS).
Five months into the COVID-19 pandemic, the world is at 29,119,433 confirmed cases of SARS-Cov2 infection, including 925,965 deaths (6 August 2020 https://covid19.who.int/), which is
We take a look into why so many zebrafish groups struggle to achieve knock-in transgenesis and what makes knock-ins so difficult.
Our CSO explores a theory he has about the amino acid arginine which seems to be showing frequent association with pathogenicity.
NemaMetrix is the market leader for early preclinical in-vivo testing using small animal models to gain a better understanding of the efficacy, mode of action, toxicity and potential targets for novel compounds. In this case study we outline how we used the animal model C. elegans to perform a set of specific experiments designed by our experts to provide rapid and reliable data based on our customer’s priorities. Using the data that we provided, our customer was able to apply for multiple patents in a timely manner.
Our CSO revisits his Veritas Genomic Sequencing report for a closer look at how significant some of the discovered variants are
When you receive your genomic report, you have a movement of trepidation.What will it say? Will it have something that says you should do countermeasures
There is a significant pressure to increase diagnostic yield and it has its consequences. BRCA testing is probably the most developed ecosystem for genetic tests
The Child Neurology Society honored William (Bill) Dobyns for his highly impactful efforts in characterizing child neurology. In a prolific and highly influential carrier, Bill
Genetic Testing Clinical geneticists have an acute need to understand pathogenicity in genomes of their patients (Figure 1). Cost per human genome has now approached
How to better understanding Variants of Uncertain Significance in epilepsy and help find new therapeutic approaches Did you know that 1 in 26 people will
“Risky Business” Most of us are wired to be risk averse. Yet, I have been giving serious contemplation to the “risky business” of having my whole
Systems for Functional Studies A variety of modeling systems can be used to explore variant function. Initially, many researchers turn to a computational approach to
The philosopher Friedrich Nietzsche once said: “You have evolved from worm to man, but much within you is still worm.” Genetic diversity in individuals and
The passion to find answers is inspiring. I had the good fortune to attend the KCNQ2 Cure Summit 2018. Meeting the patient families and seeing
The philosopher Friedrich Nietzsche once said: “You have evolved from worm to man, but much within you is still worm.” Genetic diversity in individuals and
Epilepsy Genetics 1 out of 100 persons is living with active epilepsy (Zack and Kobau 2017, WHO 2018). For the subset that can be pinned
The InVivo Biosystems Newsletter is delivered to your inbox bi-weekly,
giving you all of the latest company updates, industry news, and more.
An expert in CRISPR genome editing, InVivo Biosystems creates custom genome-edited C. elegans and zebrafish models to enable aging, developmental, and disease studies. Our unique in vivo platforms and technologies bridge the gap between cells and mice.
In Vivo Models
